Lab
American Medical Lab LTD
American Medical Lab LTD was paid $1.24M by Medicaid between Jan 2018 and Dec 2024, across 79 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 21% of everything it billed.
33Billing provider infoAMERICAN MEDICAL LAB LTD
CHICAGO RIDGE, IL 60415
CHICAGO RIDGE, IL 60415
33aNPI1699173013assigned 12/17/2014
33bProvider typeClinical Medical Laboratory
28Total paid$1.24M
24GClaims94,348
24DCodes billed79
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Illinois
Rank by total paid#68 of 235
Median peer was paid$123K
This provider vs. median10×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,980 | $33K | |
| 2019 | 7,966 | $101K | |
| 2020 | 19,731 | $562K | |
| 2021 | 18,953 | $205K | |
| 2022 | 12,192 | $108K | |
| 2023 | 20,125 | $120K | |
| 2024incomplete | 11,401 | $113K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 21% | 965 | 554 | $266K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 17% | 3,075 | 1,963 | $210K |
| 80053 | Comprehensive metabolic panel | 7.3% | 12,249 | 9,044 | $91K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.8% | 17,556 | 12,322 | $85K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 5.8% | 1,761 | 1,033 | $72K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 5.1% | 934 | 513 | $64K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.9% | 3,265 | 2,830 | $36K |
| 87486 | 2.8% | 915 | 510 | $35K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.7% | 2,045 | 1,253 | $33K |
| 87581 | 2.6% | 914 | 509 | $33K | |
| 87631 | 2.3% | 320 | 314 | $29K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.8% | 1,413 | 865 | $23K |
67 more codes
| 82728 | 1.7% | 3,358 | $22K | |
| 84466 | 1.6% | 2,784 | $20K | |
| 83735 | 1.4% | 3,081 | $17K | |
| 82607 | 1.3% | 1,952 | $17K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.3% | 1,607 | $16K |
| 83615 | 1.2% | 3,317 | $15K | |
| 83540 | 1.1% | 2,847 | $14K | |
| 80061 | Lipid panel | <1% | 2,285 | $11K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 500 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 515 | $10K |
| 82746 | <1% | 1,079 | $9K | |
| 84439 | <1% | 1,227 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,734 | $8K |
| 84075 | <1% | 1,503 | $6K | |
| 82565 | <1% | 1,550 | $6K | |
| 82435 | <1% | 1,550 | $6K | |
| 82310 | <1% | 1,508 | $6K | |
| 82040 | <1% | 1,506 | $6K | |
| 82247 | <1% | 1,505 | $6K | |
| 80050 | General health panel | <1% | 175 | $4K |
| 82533 | <1% | 351 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 745 | $4K |
| 84450 | <1% | 996 | $4K | |
| 85610 | <1% | 1,166 | $4K | |
| 84132 | <1% | 1,007 | $4K | |
| 80164 | <1% | 426 | $3K | |
| 84460 | <1% | 510 | $2K | |
| 82378 | <1% | 252 | $2K | |
| 83970 | <1% | 69 | $2K | |
| 83550 | <1% | 522 | $2K | |
| 82947 | <1% | 537 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 225 | $2K |
| 86300 | <1% | 60 | $1K | |
| 84481 | <1% | 156 | $1K | |
| 84153 | <1% | 112 | $1K | |
| 86140 | <1% | 290 | $1K | |
| 81007 | <1% | 52 | $986.36 | |
| 84480 | <1% | 123 | $977.59 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,168 | $859.67 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 17 | $688.87 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 34 | $681.73 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 16 | $644.31 |
| 84550 | <1% | 160 | $589.36 | |
| 87077 | <1% | 139 | $583.35 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 12 | $581.59 |
| 81001 | <1% | 224 | $477.99 | |
| 86803 | <1% | 35 | $412.44 | |
| 85652 | <1% | 157 | $376.89 | |
| 80074 | <1% | 12 | $317.58 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 113 | $315.34 |
| 87340 | <1% | 35 | $295.57 | |
| 84146 | <1% | 33 | $279.87 | |
| 86592 | <1% | 107 | $252.98 | |
| 84100 | <1% | 86 | $208.30 | |
| 86709 | <1% | 30 | $194.80 | |
| 86696 | <1% | 13 | $193.95 | |
| 82248 | <1% | 89 | $191.84 | |
| 82570 | <1% | 42 | $180.64 | |
| 86780 | <1% | 17 | $177.75 | |
| 86695 | <1% | 17 | $177.08 | |
| 87088 | <1% | 19 | $152.64 | |
| 82043 | <1% | 39 | $149.01 | |
| 80076 | <1% | 49 | $148.02 | |
| 82784 | <1% | 32 | $141.33 | |
| 87186 | <1% | 15 | $111.10 | |
| 83883 | <1% | 16 | $81.28 | |
| 81015 | <1% | 28 | $35.60 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBISHOP, JENNIFER (CEO)